desloratadine / Generic mfg. - LARVOL DELTA

Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer (clinicaltrials.gov) - P2 | N=46 | Not yet recruiting | Sponsor: University of Southern California

New P2 trial • Hepatocellular Cancer • Liver Cancer • Melanoma • Oncology • Solid Tumor

DESPRIN: A Study to Evaluate DEP114 for the Treatment of Acute Exacerbation of Persistent Allergic Rhinitis in Children Aged 6 to Under 12 Years (clinicaltrials.gov) - P3 | N=316 | Not yet recruiting | Sponsor: EMS

New P3 trial • Allergic Rhinitis • Immunology • Inflammation

Oral isotretinoin plus desloratadine for acne vulgaris: an updated global meta-analysis of efficacy, safety, and patient-centered outcomes (EADV 2026) - No abstract available

Retrospective data • Acne Vulgaris • Dermatology

Isotretinoin Plus Desloratadine for Acne Vulgaris: A Systematic Review and Meta-analysis of Randomised Controlled Trials (EADV 2026) - No abstract available

Retrospective data • Review • Acne Vulgaris • Dermatology

Impact of the Antihistamine Desloratadine on the Quality of Life and Dysmenorrhea in Patients With Endometriosis (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Medical University of Vienna

HEOR • New P2 trial • Endometriosis • Gynecology • Musculoskeletal Pain • Pain • Women's Health

"Green spectrophotometric determination of rupatadine, its toxic impurity, and methyl paraben: comparative AI-assisted univariate versus multivariate chemometrics". (PubMed, Sci Rep) - "Sensitive and selective green UV-spectrophotometric univariate and multivariate chemometric methods were developed to resolve the overlapped spectra of rupatadine fumarate (RUP), its impurity desloratadine (DES), and methyl paraben (MP). The results obtained were reliable and reproducible, confirming the suitability of these methods for routine analysis and quality control in laboratories. Moreover, the GLANCE tool (Graphical Layout for Analytical Chemistry Evaluation) offered a clear visual summary of the twelve structured method attributes."

Clinical • Journal

Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial. (PubMed, Cancer) - P2 | "To the authors' knowledge, this is the first study to prospectively present that aprepitant elicited a better and faster response and mild toxicity for managing EGFR-TKI induced pruritus than desloratadine."

Clinical • Journal • P2 data • Constipation • Dermatology • Gastroenterology • Gastrointestinal Disorder • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pruritus • Solid Tumor • Xerostomia • EGFR

Second-generation H1 antihistamines for the treatment of chronic urticaria: a network meta-analysis. (PubMed, Front Med (Lausanne)) - "To evaluate the efficacy and safety of 10 commonly used second-generation H1 antihistamines (cetirizine, levocetirizine, loratadine, desloratadine, ebastine, bilastine, olopatadine, rupatadine, fexofenadine, and mizolastine) at licensed doses in treating chronic urticaria using network meta-analysis. In addition, fexofenadine had the lowest incidence of adverse reactions. However, the conclusions of this study still need to be validated by further high-quality randomized controlled trials."

Journal • Retrospective data • Review • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

DETOXp: Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer (clinicaltrials.gov) - P2 | N=116 | Recruiting | Sponsor: Montefiore Medical Center | Trial completion date: Sep 2030 ➔ Dec 2030 | Trial primary completion date: Sep 2029 ➔ Dec 2029

Trial completion date • Trial primary completion date • Breast Cancer • Oncology • Solid Tumor

A prospective, observational study of efficacy and safety of desloratadine and bilastine in patients of chronic spontaneous urticaria. (PubMed, Perspect Clin Res) - "Adverse events were reported more in the desloratadine group. Bilastine is equally efficacious as desloratadine, and a favourable safety profile may make it a more tolerable H1-antihistaminic than desloratadine."

Journal • Observational data • Cardiovascular • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Efficacy of ultraviolet irradiation of pharmaceutical excipients in mitigating N-nitrosamine generation. (PubMed, J Pharm Sci) - "Desloratadine was used as a secondary amine model to evaluate the generation of N-nitrosamine in physical mixtures with various excipients...In a formulation study, 365 nm UV irradiation successfully reduced NDLRT generation in the tablet by 54-68% compared with the control. Overall, the novel strategy described herein should be useful for reducing NOCs without affecting the quality of drugs."

Journal

DESCUBRA: Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine (clinicaltrials.gov) - P3 | N=70 | Completed | Sponsor: Laboratorios Silanes S.A. de C.V. | Trial completion date: Jun 2025 ➔ Nov 2025 | Trial primary completion date: May 2025 ➔ Oct 2025 | Recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Allergic Rhinitis • Immunology • Inflammation

Efficacy and safety of Serplulimab combined with platinum-based chemotherapy and H1 receptor antagonist (desloratadine) in the First-line Treatment for locally advanced or metastatic non-small cell lung cancer?a prospective randomized controlled study (ChiCTR) - P=N/A | N=120 | Recruiting | Sponsor: Ningbo Medical Centre Lihuili Hospital; Ningbo Medical Centre Lihuili Hospital

New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR

The incidence of sleepiness in newer-generation antihistamine users: a systematic review and network meta-analysis. (PubMed, Eur J Clin Pharmacol) - "All nonsedating antihistamines administered at their usual doses have a higher prevalence of sleepiness compared to the placebo. However, most of the prevalence values are not statistically different from those of the placebo."

Clinical • Journal • Retrospective data • Review

Discovery and Mechanism of Action of a Novel Desloratadine Derivative Inhibiting Mycobacterium tuberculosis 3-Dehydroquinate Synthase. (PubMed, J Chem Inf Model) - "Collectively, the genetic, biochemical, and computational findings support DHQS as a biologically relevant target associated with DL25 activity and establish DL25 as a promising lead-like scaffold for the development of future shikimate pathway-directed antimycobacterial agents. More broadly, this study demonstrates the value of integrating genetic, biochemical, and computational approaches for mechanism-guided antituberculosis drug discovery."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Plant-Derived Diamine Oxidase Modulation of Histamine-Induced Ca2+ Release in Intestinal Caco-2 Cells: A Cellular System to Evaluate Its Histaminase Efficacy. (PubMed, Cells) - "Notably, at a fixed histamine concentration sufficient to trigger Ca2+ release, vDAO achieved the same level of calcium mobility inhibition at a concentration three-fold lower than that of desloratadine, suggesting a high efficiency of DAO. These findings indicate that histamine degradation with orally administrable DAO may reduce Ca2+ signaling in intestinal epithelial cells, providing a promising approach to reduce histamine-related damage or a reinforcement of current antihistamine anti-inflammatory medication based on histamine receptor blockade."

Journal • Allergy • CNS Disorders • Gastrointestinal Disorder

Forecasting seasonal allergic rhinitis through integrated analysis of social media and online drug sales data. (PubMed, World Allergy Organ J) - "We analyzed daily data for urban Beijing from March 1, 2022 to October 15, 2024, including pollen concentration (grains per 1000 mm3), the Baidu search index for "allergic rhinitis," and online purchase rates of 4 oral second-generation H1-antihistamines (loratadine, desloratadine, cetirizine, levocetirizine) from the Meituan platform, standardized per 100,000 population. The ARIMAX (1,1,1) model integrating both pollen and Baidu Index achieved the best forecasting performance (1-day RMSE = 3.80, MAPE = 7.68%, PCC = 0.89) and consistently outperformed single-predictor models and the random-walk benchmark across all horizons. Pollen exposure influences antihistamine demand both directly and indirectly through public information-seeking behavior captured by the Baidu Index, and integrating environmental and digital data enables timely surveillance of seasonal allergic-rhinitis-related medication use."

Journal • Allergic Rhinitis • Immunology • Inflammation

Desloratadine Rescues Schizophrenia-like Phenotypes by Inhibiting the Pathogenic 5-HT2AR-PI3K/AKT/mTOR Signaling Axis. (PubMed, Mol Neurobiol) - "Here, we show that the antihistamine desloratadine (DLT) robustly ameliorates a full spectrum of SCZ-like behavioral deficits in an MK-801-induced male mouse model. Collectively, our findings reveal that DLT exerts its therapeutic effects by suppressing a pathogenic feed-forward loop, wherein 5-HT2AR activates the PI3K/AKT/mTOR pathway, which may, in turn, sustain its own aberrant expression. This study provides a compelling rationale for repurposing desloratadine for SCZ and validates the 5-HT2AR-PI3K/AKT/mTOR signaling axis as a pivotal, druggable target for therapeutic intervention."

Journal • CNS Disorders • Inflammation • Psychiatry • Schizophrenia

Pharmaceutical care in self-medication: ABC/VED analysis of over-the-counter antiallergic medicines. (PubMed, Ceska Slov Farm) - "The integrated ABC/VED approach is an effective tool for identifying priority OTC antiallergic medicines, supporting rational pharmacy assortment management, supporting evidence-based practice and pharmaceutical care in self-medication under limited healthcare resources."

Journal • Allergy • Immunology

Risk of drug-related aggression in pediatric populations: a pharmacovigilance analysis using the FAERS database. (PubMed, Front Pediatr) - "Signals for tezacaftor, elexacaftor, macrogol, desloratadine, and ebastine were identified despite absent FDA label warnings. The strongest signals were for ebastine (ROR: 23.40) and perampanel (17.41), while montelukast had the highest case volume (N = 1,392). Most drugs showed the highest aRORs in early childhood, except levetiracetam, which peaked in adolescence...This study identifies robust signals linking multiple drugs to pediatric aggression, with elevated risks observed particularly in younger children and females. These findings underscore the need for heightened clinical vigilance, consideration of demographic-specific risks, and updated regulatory labeling to improve pediatric drug safety."

Adverse events • Journal • Pediatrics

Second-generation H1 antihistamine use with survival and immune-related outcomes in lung cancer and melanoma patients receiving immune checkpoint inhibitors. (ASCO 2026) - "Adult patients (≥18 years) with melanoma or lung cancer receiving ICIs (pembrolizumab, nivolumab, ipilimumab, atezolizumab, durvalumab, cemiplimab, or avelumab) were identified. Patients were categorized by exposure to second-generation H1 antihistamines (cetirizine, loratadine, fexofenadine, desloratadine, or levocetirizine) within 3 months before or during ICI initiation... Second-generation H1 antihistamine use was associated with improved early survival and reduced healthcare utilization among melanoma and lung cancer patients treated with ICIs, without a significant increase in irAEs. Despite the retrospective design and potential confounding, prospective validation is warranted."

Checkpoint inhibition • Clinical • Lung Cancer • Melanoma • Musculoskeletal Diseases • Neutropenia • Oncology • Solid Tumor

Discrimination of crystal polymorphism in active pharmaceutical ingredients using time-domain 1H NMR relaxation combined with multivariate statistical process control. (PubMed, Int J Pharm) - "Desloratadine, linagliptin, and carbamazepine, each exhibiting multiple polymorphic forms, were selected as model APIs. TD-NMR offers practical advantages, including rapid measurement, minimal sample preparation, and non-destructive analysis using low-field benchtop instruments. These results indicate that TD-NMR combined with MSPC provides a practical at-line method for monitoring crystal polymorphism and detecting polymorphic contamination during pharmaceutical manufacturing."

Journal

Desloratadine as Adjunct Therapy for Rheumatoid Arthritis (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Horus University

New P2 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Multiple Hypersensitivity Reactions to Chemically Unrelated H1 Antihistamines: Two Case Reports (EAACI 2026) - "During subsequent diagnostic work-up, double-blindplacebo-controlled provocation tests (DBPC) were performed with levocetirizine (10mg), fexofenadine (180 mg), desloratadine (5 mg), and bilastine (20 mg)...Subsequently, a provocation test with rupatadine (cumulativedose 10 mg) was performed... The presented cases confirm the possibility of paradoxical hypersensitivity reactionsto antihistamines. To the best of our knowledge, this is the first report describinghypersensitivity reactions to multiple H1 antihistamines with different chemicalstructures."

Case report • Clinical • Immunology

Asymptomatıc QT Prolongatıon Developıng After Antıhıstamıne Use (EAACI 2026) - "Based on these findings, levocetirizine, desloratadine, and chlorpheniramine maleate were considered as possible agents responsible for QT prolongation. This case demonstrates that even second and third-generation antihistamines can prolong the QT interval in some clinical conditions. When incidental QT prolongation is detected in asymptomatic children, a detailed inquiry into the medication history, especially careful evaluation of QT-prolonging drug combinations, is important. The return of the QT interval to normal upon discontinuation of the drug supports the idea that QT prolongation caused by antihistamines is temporary and reversible."

Allergic Rhinitis • Immunology • Inflammation